Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients
1 other identifier
interventional
74
1 country
1
Brief Summary
This is a research that will investigate the safety and efficacy of virgin coconut oil (VCO) as an adjunctive therapy for Coronavirus Disease 2019 (COVID-19)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2 covid19
Started Oct 2020
Longer than P75 for phase_2 covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 22, 2020
CompletedFirst Submitted
Initial submission to the registry
March 19, 2021
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 9, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 9, 2022
CompletedMarch 8, 2022
March 1, 2022
1.5 years
March 19, 2021
March 7, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Duration of hospital stay
To determine if the VCO intervention can lessen the duration of stay in the hospital by at least 2 days
Two weeks
Time to recovery/resolution of symptoms
Patient will be assessed based on the following secondary outcome: time interval before ventilation, ICU and negative results on PCR swab test
Two weeks
Secondary Outcomes (10)
Time to first receipt of ventilation and admission to intensive care unit
Two weeks
IL-6 levels (pg/mL)
Two weeks
Ferritin levels (ng/mL)
Two weeks
CRP levels (mg/dL)
Two weeks
LDH levels (mg/dL0
Two weeks
- +5 more secondary outcomes
Other Outcomes (1)
Negative test result for COVID by RT-PCR
Two weeks
Study Arms (2)
Standard of care plus adjunctive virgin coconut oil supplementation
EXPERIMENTALStandard of care plus virgin coconut oil
COVID-19 Standard of care treatment
NO INTERVENTIONStandard of care
Interventions
Oral supplementation of virgin coconut oil to COVID-19 patients
Eligibility Criteria
You may qualify if:
- symptomatic and asymptomatic COVID-19 hospitalized patients
- has laboratory-confirmed illness during the time of recruitment
- able to take food and medicines enterally
You may not qualify if:
- uncontrolled or newly diagnosed diabetes mellitus
- with chronic heart disease
- having elevated lipid profile at baseline (admission)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of the Philippineslead
- Philippine Coconut Authoritycollaborator
- Philippine Council for Health Research & Developmentcollaborator
Study Sites (1)
Philippine General Hospital
Manila, National Capital Region, 1000, Philippines
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marissa M Alejandria, MD
UP Manila
- PRINCIPAL INVESTIGATOR
Leslie Michelle M Dalmacio, PhD
UP Manila
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 19, 2021
First Posted
April 19, 2021
Study Start
October 22, 2020
Primary Completion
April 9, 2022
Study Completion
April 9, 2022
Last Updated
March 8, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share